Immunology Biosimilars Market Size In 2026: Regional Growth, Key Segments And Future Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Immunology Biosimilars Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The immunology biosimilars market has seen substantial growth in recent years. It is anticipated to increase from $8.35 billion in 2025 to $9.45 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. Historically, this growth can be attributed to several factors including the elevated cost of original biologics, the restricted availability of biosimilar options, the rising occurrence of autoimmune diseases, the expanding integration of biologics in hospital and clinical practices, and the rigorous regulatory approval processes for biosimilars.
The immunology biosimilars market is set for significant expansion in the coming years, with its size expected to grow to $15.3 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.8%. This projected increase can be attributed to factors such as the development of advanced biosimilar molecules, the expansion of homecare and outpatient treatment options, increasing regulatory harmonization, rising patient awareness and acceptance, and the growth of online and hospital pharmacy distribution channels. Noteworthy trends during this forecast period include the rising adoption of monoclonal antibody biosimilars, increasing use of fusion protein biosimilars, the expansion of recombinant protein therapies, a growing market for interferon-based treatments, and enhanced access to affordable immunology therapies.
Get A Free Sample Report With In-Depth Market Insights:
Immunology Biosimilars Market Growth Catalysts And Demand Drivers
The rising occurrence of chronic immunological conditions is projected to boost the expansion of the immunology biosimilars market. Chronic immunological conditions are persistent disorders where the immune system malfunctions, either attacking the body’s tissues or failing to offer effective protection. This increase in chronic immunological conditions is attributed to a growing number of individuals affected by long-term immune system disorders that demand continuous treatment, proactive disease management, and ongoing healthcare support. Immunology biosimilars address chronic immunological conditions by providing affordable and effective treatment alternatives, supporting long-term disease management, and enhancing patient access to essential therapies that control immune system dysfunction. For instance, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization dedicated to global MS research and advocacy, estimated that 2.9 million people worldwide were living with multiple sclerosis in 2023. Therefore, the increasing prevalence of chronic immunological conditions is stimulating growth within the immunology biosimilars market.
Immunology Biosimilars Market Segment Analysis: What Are The Core Market Categories?
The immunology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators
2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies
2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars
3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars
4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma
5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars
Immunology Biosimilars Market Trends Shaping Long-Term Demand
Leading companies within the immunology biosimilars market are dedicating efforts to creating advanced biosimilar innovations, encompassing expected interchangeability designations, improved formulations with enhanced stability, and new delivery methods, all designed to offer patients more accessible and effective treatment options. An anticipated interchangeability designation indicates that the biosimilar is forecast to satisfy regulatory criteria, permitting its substitution for the original biologic drug at the pharmacy without needing the prescriber’s involvement. For example, in February 2025, Sandoz Group AG, a pharmaceutical company based in Switzerland, introduced Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, intended for managing chronic autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This launch, executed in collaboration with Samsung Bioepis Co. Ltd., a biopharmaceutical firm from South Korea, highlights Sandoz’s commitment to broadening access to immunology biosimilars by providing an economical and patient-centric therapy that includes multiple dosing choices, extended stability, and the unique feature of being re-refrigerated after initial cooling.
Immunology Biosimilars Market Top Companies Driving Competitive Growth
Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.
View The Full Immunology Biosimilars Market Report:
Immunology Biosimilars Market Regional Analysis And Leading Geography
North America was the largest region in the immunology biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
